期刊文献+
共找到809篇文章
< 1 2 41 >
每页显示 20 50 100
Left bundle branch pacing vs biventricular pacing in heart failure patients with left bundle branch block:A systematic review and meta-analysis 被引量:3
1
作者 Farah Yasmin Abdul Moeed +7 位作者 Rohan Kumar Ochani Hamna Raheel Malik Ali Ehtsham Awan Ayesha Liaquat Arisha Saleem Muhammad Aamir Nael Hawwa Salim Surani 《World Journal of Cardiology》 2024年第1期40-48,共9页
BACKGROUND Left bundle branch pacing(LBBP)is a novel pacing modality of cardiac resynchronization therapy(CRT)that achieves more physiologic native ventricular activation than biventricular pacing(BiVP).AIM To explore... BACKGROUND Left bundle branch pacing(LBBP)is a novel pacing modality of cardiac resynchronization therapy(CRT)that achieves more physiologic native ventricular activation than biventricular pacing(BiVP).AIM To explore the validity of electromechanical resynchronization,clinical and echocardiographic response of LBBP-CRT.METHODS Systematic review and Meta-analysis were conducted in accordance with the standard guidelines as mentioned in detail in the methodology section.RESULTS In our analysis,the success rate of LBBP-CRT was determined to be 91.1%.LBBP CRT significantly shortened QRS duration,with significant improvement in echocardiographic parameters,including left ventricular ejection fraction,left ventricular end-diastolic diameter and left ventricular end-systolic diameter in comparison with BiVP-CRT.CONCLUSION A significant reduction in New York Heart Association class and B-type natriuretic peptide levels was also observed in the LBBP-CRT group vs BiVP-CRT group.Lastly,the LBBP-CRT cohort had a reduced pacing threshold at follow-up as compared to BiVP-CRT. 展开更多
关键词 left bundle branch pacing Biventricular pacing QRS duration left ventricular ejection fraction heart failure
下载PDF
Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
2
作者 Filippos Triposkiadis Grigorios Giamouzis +1 位作者 John Skoularigis Andrew Xanthopoulos 《World Journal of Clinical Cases》 SCIE 2022年第32期12052-12055,共4页
The present work discusses the serious confusion resulting from the arbitrary nomenclature of heart failure with preserved ejection fraction(HFpEF),the presumed underlying pathophysiology,and the supposed features.A c... The present work discusses the serious confusion resulting from the arbitrary nomenclature of heart failure with preserved ejection fraction(HFpEF),the presumed underlying pathophysiology,and the supposed features.A consequence of this misconception is that HFpEF trials have recruited patients with entirely different characteristics rendering the extrapolation of the results of one study to the other infeasible and dramatically affecting diagnosis and treatment. 展开更多
关键词 heart failure PRESERVED NOMENCLATURE left ventricular ejection fraction PATHOPHYSIOLOGY Phenotypic persistence
下载PDF
Clinical characteristics and prognosis of heart failure with normal left ventricular ejection fraction in elderly patients 被引量:9
3
作者 LIU De-ping WANG Fan +1 位作者 ZENG Xue-zhai ZHANG Xin-chao 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第16期2853-2857,共5页
Background The term heart failure with normal ejection fraction (HFNEF) is often used to describe the syndrome of heart failure with normal ejection fraction. Based on the previous studies, HFNEF has a significant m... Background The term heart failure with normal ejection fraction (HFNEF) is often used to describe the syndrome of heart failure with normal ejection fraction. Based on the previous studies, HFNEF has a significant morbidity and mortality and is associated with a similar prognosis to heart failure with reduced ejection fraction (HFREF). The present study aimed to investigate the clinical characteristics and prognosis of HFNEF in elderly patients. Methods Consecutive elderly patients (〉60 years old) hospitalized for the first episode of heart failure (HF) in Beijing Hospital from January 2003 to December 2009 were retrospectively recruited. Three hundred and ten patients with HF were eligible for our study. As recently recommended, a cut-off value of 50% was used to distinguish HFNEF (LVEF〉50%) from HFREF (LVEF〈50%). Data were retrospectively obtained from hospital records and databases. Follow-up data were obtained by telephone and from hospital records. For every eligible patient, the clinical characteristics and prognosis were collected and compared between the HFNEF and HFREF groups. Results Patients with HFNEF accounted for 54.5% of all cases of elderly patients with HF. Compared with HFREF, the elderly patients with HFNEF had a higher proportion of females (62.1% vs. 32.6%, P 〈0.001), higher body mass index (BMI) ((24.9±4.7) vs. (23.5±4.0) kg/m2, P=0.011), higher systolic blood pressure at admission ((141.5±22.6) vs. (134.3±18.6) mmHg, P=0.002), but lower hemoglobin levels ((118.3±22.7) vs. (125.8±23.8) g/L, P=0.005). The incidence of coronary heart disease (43.2% vs. 65.2%, P 〈0.001) and myocardial infarction (16.6% vs. 46.1%, P 〈0.001) were significantly lower in elderly patients with HFNEF than in those with HFREF (P 〈0.001). With a mean follow-up of 33.5 (0.5-93) months, 120 patients (38.7%) died, including 94 (30.3%) cardiac deaths. The HFNEF group had fewer deaths than the HFREF group at the end of the first follow-up (46/169 (27.2%) vs. 58/141 (41.1%)) and at the end of the second follow-up (56/169 (33.1%) vs. 64/141 (45.4%)). Kaplan-Meier survival analysis showed a significantly higher survival rate in elderly patients with HFNEF than those with HFREF (P=0.021 for total mortality and P 〈0.001 for cardiac mortality). Multiple Logistic regression analysis showed that LVEF 〈50% was an independent risk factor for death in elderly patients with HF. Conclusions More than half of elderly patients with HF have a normal LVEF. The prognosis of the elderly patients with HFNEF is poor, though slightly better than the elderly patients with HFREF. 展开更多
关键词 heart failure left ventricular ejection fraction PROGNOSIS
原文传递
Preferred Revascularization Strategies in Patients with Ischemic Heart Failure: A Meta-Analysis 被引量:2
4
作者 Jie XIAO Fen XU +5 位作者 Chuan-lei YANG Wei-qiang CHEN Xing CHEN Hua ZHANG Zhan-jie WEI Jin-ping LIU 《Current Medical Science》 SCIE CAS 2018年第5期776-784,共9页
Clinically,coronary artery bypass grafting (CABG)or percutaneous coronary intervention (PCI)is generally used to treat patients with ischemic heart failure.However, the optimal treatment strategy remains unknown.This ... Clinically,coronary artery bypass grafting (CABG)or percutaneous coronary intervention (PCI)is generally used to treat patients with ischemic heart failure.However, the optimal treatment strategy remains unknown.This study examined the efficacy of the two coronary revascularization strategies for severe ischemic heart failure by using a meta-analysis.Studies comparing the efficacy of CABG and PCI were obtained from PubMed,EMBASE,Google Scholar and Cochrane Central Register of Controlled Trials (CENTRAL).The quality of each eligible article was evaluated by Newcastle-Ottawa Quality Assessment Scale (NOS),and the meta-analysis was performed using Stata version 12.0 software.Eventually,12 studies involving 9248 patients (n=4872 in CABG group;n=4376 in PCI group)were subject to the meta-analysis for subsequent pooling calculation.The pooled hazard ratio (HR)[HR=0.83,95%CI (0.76,0.90),P<0.001; heterogeneity,P=0.218,I^2=22.9%]of CABG compared with that of PCI revealed a statistical superiority of CABG to PCI in terms of the long-term mortality.Furthermore, CABG showed more advantages over PCI with respect to the incidence of myocardial infarction [HR=0.51,95%CI (0.39,0.67),P<0.001;heterogeneity,P=-0.707,I^2=0%]and repeat revascularization [HR=0.40,95%CI (0.27,0.59),P<0.001;heterogeneity,P<0.001, I^2=80.1%].It was concluded that CABG appears to be more advantageous than PCI for the treatment of ischemic heart failure in the given clinical setting. 展开更多
关键词 CORONARY ARTERY disease ischemic heart failure left ventricular ejection fraction CORONARY ARTERY BYPASS grafting percutaneous CORONARY intervention
下载PDF
Left Ventricular Dysfunction: The Perspective of Echocardiography in Ghana
5
作者 Isaac Kofi Owusu Yaw Amo Wiafe 《World Journal of Cardiovascular Diseases》 2019年第9期639-648,共10页
Introduction: Ghana is one of the fastest growing economies in sub-Saharan Africa which is expected to undergo a significant epidemiologic transition because of industrialisation and economic development. Having trans... Introduction: Ghana is one of the fastest growing economies in sub-Saharan Africa which is expected to undergo a significant epidemiologic transition because of industrialisation and economic development. Having transitioned from low to middle income status recently, this study investigated the epidemiology of left ventricular dysfunction (LVD) in patients who were referred for echocardiography. Material and Methods: We conducted a retrospective cross-sectional study on an out-patient population who were referred to the Precise Specialist Clinic in Kumasi, Ghana for echocardiography, from January 2016 to December 2018. Descriptive statistical analyses were performed and the results summarised in the proportions, tables and pie charts. Categorical variables and proportions were compared using Fisher’s exact test and test of proportions respectively. P-value Results: The results show that 61% of the out-patient population referred for echocardiography between 2016 and 2018 had LVD at a mean age of 59 years. In this LVD population, Heart Failure with preserved ejection fraction (HFpEF) and Heart Failure with reduced ejection fraction (HFrEF) accounted for 73% and 27% respectively. The majority of patients with HFrEF also had left ventricular diastolic dysfunction, mitral regurgitation and tricuspid regurgitation.Conclusion: This study shows that, HFpEF was seen in over 70% of patients with LVD, and it occurred at a relatively younger age. Efforts should be made for prevention, early detection and control of conditions such as hypertension, diabetes and obesity which have been shown to be associated with HFpEF. 展开更多
关键词 left ventricular DYSFUNCTION heart failure with PRESERVED ejection fraction SYSTOLIC DYSFUNCTION Ghana
下载PDF
Left bundle branch area pacing:A new era of cardiac resynchronization therapy?
6
作者 Carlo Alberto Caruzzo Elia Rigamonti Francesca Romana Scopigni 《World Journal of Cardiology》 2024年第9期542-545,共4页
The recent systematic review and meta-analysis provided a comprehensive focus on the current state of cardiac resynchronization therapy(CRT).The authors determined the feasibility of physiological left bundle branch a... The recent systematic review and meta-analysis provided a comprehensive focus on the current state of cardiac resynchronization therapy(CRT).The authors determined the feasibility of physiological left bundle branch area pacing(LBBAP)in patients indicated for CRT through a careful analysis of trials.They found that LBBAP was associated with significant reductions in QRS duration,New York Heart Association functional class,B-type natriuretic peptide levels,and pacing thresholds as well as improvements in echocardiographic parameters compared to biventricular pacing. 展开更多
关键词 left bundle branch pacing Biventricular pacing QRS duration left ventricular ejection fraction heart failure
下载PDF
Comparative breakthrough: Umbilical cord mesenchymal stem cells vs bone marrow mesenchymal stem cells in heart failure treatment
7
作者 Peng Li 《World Journal of Cardiology》 2024年第12期776-780,共5页
In this article,we evaluate the comparative efficacy and safety of mesenchymal stem cells(MSCs)derived from bone marrow(BM-MSCs)and umbilical cord(UC-MSCs)in the treatment of heart failure and myocardial infarction.MS... In this article,we evaluate the comparative efficacy and safety of mesenchymal stem cells(MSCs)derived from bone marrow(BM-MSCs)and umbilical cord(UC-MSCs)in the treatment of heart failure and myocardial infarction.MSCs have gained importance as living bio drug due to their regenerative potential,with BM-MSCs being the most extensively studied.However,UC-MSCs offer unique advantages,such as noninvasive collection and fewer ethical concerns.This systematic review and meta-analysis summarizes data from 13 randomized controlled trials,which included a total of 693 patients.Their study shows that UC-MSCs significantly improved left ventricular ejection fraction by 5.08%at 6 months and 2.78%at 12 months compared with controls,while BM-MSCs showed no significant effect.Neither cell type showed significant changes in 6-minute walk distance.In addition,UC-MSCs and BM-MSCs had comparable safety profiles,with no significant differences in major adverse cardiac events,except for a lower rehospitalization rate observed with BM-MSCs.These results position UC-MSCs as a promising alternative in MSC-based therapies for cardiac disease,offering potential improvements in cardiac function while maintaining a favorable safety profile.Future research should focus on optimizing adminis-tration protocols and further exploring the long-term benefits and mechanisms of UC-MSCs in cardiac repair. 展开更多
关键词 Mesenchymal stem cells heart failure Umbilical cord-derived mesenchymal stem cells Bone marrow-derived mesenchymal stem cells left ventricular ejection fraction 6-minute walking distance Cardiac regeneration therapy
下载PDF
沙库巴曲缬沙坦对老年高血压合并HFrEF患者疗效、心功能及预后的影响 被引量:14
8
作者 马红红 张启龙 马艳梅 《海南医学》 CAS 2023年第2期210-213,共4页
目的研究沙库巴曲缬沙坦对老年高血压合并射血分数降低的心力衰竭(HFrEF)患者疗效、心功能及预后的影响。方法回顾性分析2019年1月至2021年1月在榆林市第一医院接受治疗的60例老年高血压合并HFrEF患者的诊疗资料。所有患者均使用琥珀酸... 目的研究沙库巴曲缬沙坦对老年高血压合并射血分数降低的心力衰竭(HFrEF)患者疗效、心功能及预后的影响。方法回顾性分析2019年1月至2021年1月在榆林市第一医院接受治疗的60例老年高血压合并HFrEF患者的诊疗资料。所有患者均使用琥珀酸美托洛尔及螺内酯、呋塞米常规治疗,按治疗用药不同分组。其中28例在常规治疗基础上采用氯沙坦钾治疗者纳入对照组,32例在常规治疗基础上采用沙库巴曲缬沙坦治疗者纳入观察组。治疗8周后,比较两组患者的疗效,以及治疗前及治疗8周后的左心室舒张末期内径(LVEDD)、收缩压(SBP)、舒张压(DBP)和左心室射血分数(LVEF),同时比较两组患者治疗期间的不良反应发生情况;随访6个月,比较两组患者心源性猝死和心力衰竭再入院情况。结果治疗8周后,观察组患者的治疗总有效率为93.33%,明显高于对照组的73.33%,差异有统计学意义(P<0.05);治疗前,两组患者的SBP、DBP、LVEDD、LVEF比较差异均无统计学意义(P>0.05);治疗8周后,观察组患者的SBP、DBP、LVEDD分别为(128.91±8.84)mmHg、(83.72±7.01)mmHg、(55.24±6.74)mm,明显低于对照组的(143.31±9.83)mmHg、(90.71±8.51)mmHg、(49.78±6.52)mm,而LVEF为(42.56±7.82)%,明显高于对照组的(35.68±8.54)%,差异均有统计学意义(P<0.05);治疗期间,观察组患者的不良反应发生率为6.67%,略低于对照组的10.00%,但差异无统计学意义(P<0.05);随访6个月,两组患者的心源性猝死率比较差异无统计学意义(P<0.05),而观察组患者的心力衰竭再入院率为6.67%,明显低于对照组的26.67%,差异有统计学意义(P<0.05)。结论沙库巴曲缬沙坦能显著改善老年高血压合并慢性心力衰竭患者的血压及心功能,临床应用效果显著,值得推广应用。 展开更多
关键词 慢性射血分数降低的心力衰竭 高血压 沙库巴曲缬沙坦 疗效 不良反应
下载PDF
达格列净治疗2型糖尿病合并HFrEF患者心功能变化的评价分析 被引量:3
9
作者 雷煌平 蓝胜峰 《药品评价》 CAS 2023年第6期729-732,共4页
目的探讨达格列净治疗2型糖尿病(T2DM)合并射血分数下降的心力衰竭(HFrEF)患者的临床效果及对心功能的影响。方法选取2020年8月至2022年8月景德镇市第二人民医院收治的60例T2DM合并HFrEF患者,按随机数字表法分为两组,各30例。两组均予... 目的探讨达格列净治疗2型糖尿病(T2DM)合并射血分数下降的心力衰竭(HFrEF)患者的临床效果及对心功能的影响。方法选取2020年8月至2022年8月景德镇市第二人民医院收治的60例T2DM合并HFrEF患者,按随机数字表法分为两组,各30例。两组均予以常规抗心衰治疗,对照组予以二甲双胍治疗,观察组予以达格列净治疗,持续治疗6个月。比较两组临床疗效,心功能指标[左室射血分数(LVEF)、左室舒张末内径(LVEDd)、左室收缩末内径(LVESd)],血糖水平[糖化血红蛋白(HbA1c)、空腹血糖(FPG)水平、餐后2 h血糖(2 hPG)],N末端B型利钠肽原(NT-proBNP),炎症水平[C反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)],6 min步行距离,生活质量[世卫组织生活简易量表(WHOQOL-BREF)]及不良反应。结果观察组总有效率较对照组高。治疗后,LVEF高于对照组,LVEDd、LVESd低于对照组,差异有统计学意义(P<0.05);观察组HbA1c、FPG、2hPG低于对照组,差异有统计学意义(P<0.05);观察组NT-proBNP、CRP、IL-6、TNF-α水平低于对照组,6 min步行距离长于对照组,差异有统计学意义(P<0.05);观察组WHOQOL-BREF评分高于对照组,差异有统计学意义(P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论达格列净可提高T2DM合并HFrEF治疗效果,降低血糖水平,减轻心功能损害,改善生活质量,安全可靠。 展开更多
关键词 达格列净 糖尿病 2型 射血分数下降的心力衰竭 心功能 血糖水平
下载PDF
Heart‘omicsin’AGEing (HOMAGE):design,research objectives and characteristics of the common database 被引量:1
10
作者 Lotte Jacobs Lutgarde Thijs +21 位作者 Yu Jin Faiez Zannad Alexandre Mebazaa Philippe Rouet Florence Pinet Christophe Bauters Burkert Pieske Andreas Tomaschitz Mamas Mamas Javier Diez Kenneth McDonald John G F Cleland Hans-Peter Brunner-La Rocca Stephane Heymans Roberto Latini Serge Masson Peter Sever Christian Delles Stuart Pocock Timothy Collier Tatiana Kuznetsova Jan A Staessen 《The Journal of Biomedical Research》 CAS 2014年第5期349-359,共11页
Heart failure is common in older people and its prevalence is increasing.The Heart 'omics' in AGEing(HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure.A la... Heart failure is common in older people and its prevalence is increasing.The Heart 'omics' in AGEing(HOMAGE) project aims to provide a biomarker approach that will improve the early diagnosis of heart failure.A large clinical database,based on(1) prospective population studies or(2) cross-sectional,prospective studies or randomized controlled trials(RCTs) of patients at risk for or with overt cardiovascular disease will be constructed to determine most promising 'omics'-based biomarkers to identify the risk of developing heart failure and/or comorbidities.Population studies,patient cohorts and RCTs are eligible for inclusion in the common database,if they received ethical approval to obtain and share data and have baseline information on cardiovascular risk factors.Currently,the HOMAGE database includes 43,065 subjects,from 20 studies in eight European countries,including healthy subjects from three population studies in France,Belgium and Italy(n = 7,124),patients with heart failure(n = 4,312) from four cohorts in the UK,Spain and Switzerland and patients at high risk for cardiovascular disease(n = 31,629) in 13 cohorts.It is anticipated that more partners will join the consortium and enlarge the pooled data.This large merged database will be a useful resource with which to identify candidate biomarkers that play a role in the mechanism underlying the onset and progression of heart failure. 展开更多
关键词 left ventricle heart failure heart failure with reduced ejection fraction heart failure with preserved ejection fraction population science morbidity mortality
下载PDF
沙库巴曲缬沙坦联合培哚普利治疗HFrEF、HFmrEF及HFpEF的效果 被引量:1
11
作者 陈琳 左海朝 《河南医学研究》 CAS 2021年第26期4914-4917,共4页
目的探讨沙库巴曲缬沙坦联合培哚普利治疗左室射血分数(LVEF)下降的心力衰竭(HF)(HFrEF)、LVEF中间范围的HF(HFmrEF)和LVEF保留的HF(HFpEF)的效果。方法选取2019年10月至2020年10月新郑市中医院收治的120例HF患者作为研究对象,按照随机... 目的探讨沙库巴曲缬沙坦联合培哚普利治疗左室射血分数(LVEF)下降的心力衰竭(HF)(HFrEF)、LVEF中间范围的HF(HFmrEF)和LVEF保留的HF(HFpEF)的效果。方法选取2019年10月至2020年10月新郑市中医院收治的120例HF患者作为研究对象,按照随机数表法分为对照组和观察组,每组60例。根据心脏彩超将LVEF患者分为3个亚组:HFrEF、HFmrEF及HFpEF组。对照组接受常规抗HF联合培哚普利片治疗,观察组在对照组的基础上联合沙库巴曲缬沙坦片治疗。观察治疗前后两组氨基末端脑钠肽前体(NT-pro BNP)、LVEF、左室舒张末期内径(LVEDD)变化;观察两组不良反应发生情况;比较两组再入院率和病死率。结果治疗前,两组患者的NT-pro BNP水平比较,差异无统计学意义(P>0.05);治疗6个月后,两组患者的NT-pro BNP水平降低,差异有统计学意义(P<0.05);且观察组HFrEF和HFmrEF的NT-pro BNP水平较对照组低,差异有统计学意义(P<0.05);但两组HFpEF的NT-pro BNP水平比较,差异无统计学意义(P>0.05)。治疗前,两组患者的LVEF和LVEDD比较,差异无统计学意义(P>0.05);治疗后,两组患者的LVEF升高,LVEDD降低,差异有统计学意义(P<0.05);且观察组HFrEF及HFmrEF患者的LVEF高于对照组,差异有统计学意义(P<0.05);但两组HFpEF的LVEF比较,差异无统计学意义(P>0.05);治疗后,两组的LVEDD比较,差异无统计学意义(P>0.05)。随访期间,两组患者的药物不良反应总发生率、再入院率、病死率比较,差异均无统计学意义(P>0.05)。结论沙库巴曲缬沙坦联合培哚普利治疗不同类型HF均可降低患者NT-pro BNP水平,改善心功能。在HFrEF、HFmrEF亚组中,联合治疗的临床效果比单纯使用培哚普利更佳。 展开更多
关键词 沙库巴曲缬沙坦 培哚普利 左室射血分数下降的心力衰竭、左室射血分数中间范围的心力衰竭、左室射血分数保留的心力衰竭
下载PDF
探讨沙库巴曲缬沙坦对老年HFrEF患者心功能及血浆NT-proBNP、hs-TnT水平的影响 被引量:2
12
作者 钮黎剑 卢振华 +1 位作者 于费 何凤莲 《中国处方药》 2022年第11期163-165,共3页
目的探究与分析沙库巴曲缬沙坦对老年HFrEF患者心功能及血浆NT-proBNP、hs-TnT水平的影响。方法采取随机数字表法将自2019年2月~2021年2月收治的HFrEF患者120例分为两组,各60例,对照组给予醛固酮受体拮抗剂与β受体阻滞剂等常规药物治疗... 目的探究与分析沙库巴曲缬沙坦对老年HFrEF患者心功能及血浆NT-proBNP、hs-TnT水平的影响。方法采取随机数字表法将自2019年2月~2021年2月收治的HFrEF患者120例分为两组,各60例,对照组给予醛固酮受体拮抗剂与β受体阻滞剂等常规药物治疗,观察组在对照组的治疗基础上加用沙库巴曲缬沙坦,两组均连续治疗6个月,对比两组临床疗效、心功能指标及血浆NT-proBNP、hs-TnT水平的变化,同时观察不良反应。结果与对照组相比,观察组临床总有效率较高,差异有统计学意义(P<0.05)。与对照组治疗后相比,观察组治疗后LVESD较低、LVEF较高、LVEDd较低,LVPW较高,CO及CI较高,血浆NT-proBNP水平较低、hs-TnT水平较低,差异有统计学意义(P<0.05)。两组治疗期间均未出现严重的不良反应,也没有因严重不良反而停药退出者。结论沙库巴曲缬沙坦治疗HFrEF患者可获得更好的临床疗效,促进血浆NTproBNP、hs-TnT水平改善,减缓心肌的进一步损伤,患者治疗期间无明显不良反应,安全性较高。 展开更多
关键词 沙库巴曲缬沙坦 左心室射血分数 心力衰竭 心功能 N末端脑利钠肽前体 超敏肌钙蛋白
下载PDF
血清UA、CysC、galectin-3与HFrEF患者1年内再入院的关系研究
13
作者 李新国 李雪杰 +1 位作者 王岩 李妮妮 《检验医学与临床》 CAS 2023年第13期1867-1871,共5页
目的探讨血清尿酸(UA)、胱抑素C(CysC)及半乳糖凝集素3(galectin-3)与左心室射血分数降低的心力衰竭(HFrEF)患者1年内再入院的关系。方法纳入研究对象共180例,均为该院2018年11月至2021年2月收治的HFrEF患者。以HFrEF患者出院后1年内再... 目的探讨血清尿酸(UA)、胱抑素C(CysC)及半乳糖凝集素3(galectin-3)与左心室射血分数降低的心力衰竭(HFrEF)患者1年内再入院的关系。方法纳入研究对象共180例,均为该院2018年11月至2021年2月收治的HFrEF患者。以HFrEF患者出院后1年内再因心力衰竭入院为该研究终点,将所有患者分为再入院组(79例)与未再入院组(101例)。对比两组血清UA、CysC及galectin-3水平,以多因素Logistic回归分析HFrEF患者1年内再入院的危险因素。采用受试者工作特征(ROC)曲线探讨血清UA、CysC及galectin-3预测HFrEF患者1年内再入院的效能。结果再入院组血清UA、CysC及galectin-3水平分别为(492.75±31.82)μmol/L、(1.84±0.20)mg/L、(44.35±9.87)ng/mL,相较于未再入院组的(423.47±26.58)μmol/L、(1.12±0.17)mg/L、(32.19±5.42)ng/mL更高(P<0.05)。再入院组高血压、心包积液以及美国纽约心脏病协会(NYHA)心功能分级Ⅳ级人数占比相较于未再入院组更高(P<0.05);再入院组左心室射血分数(LVEF)低于未再入院组(P<0.05),且N末端脑钠肽前体(NT-proBNP)水平高于未再入院组(P<0.05)。多因素Logistic回归分析发现:高血压、心包积液、NYHA心功能分级Ⅲ/Ⅳ级以及血清UA、CysC、galectin-3、NT-proBNP水平升高均是HFrEF患者1年内再入院的危险因素(P<0.05),而LVEF水平升高为HFrEF患者1年内再入院的保护因素(P<0.05)。ROC曲线分析发现:血清UA、CysC及galectin-3联合预测HFrEF患者1年内再入院的效能(曲线下面积为0.866)优于上述3项指标单独预测。结论血清UA、CysC及galectin-3水平升高均是HFrEF患者出院后1年内再入院的危险因素,且血清UA、CysC及galectin-3联合检测能够辅助预测HFrEF患者出院后1年内再入院风险。 展开更多
关键词 左心室射血分数 心力衰竭 尿酸 胱抑素C 半乳糖凝集素3 再入院
下载PDF
The Prevalence and Short-Term Outcomes of Ventricular Dyssynchrony after Right Ventricular Pacing
14
作者 Thipdhorn Aritajati Kritsana Tipcome +3 位作者 Anusang Chitsomkasem Nithi Tokavanich Teetouch Ananwattanasuk Padoemwut Teerawongsakul 《International Journal of Clinical Medicine》 2021年第11期459-470,共12页
Objective: Long-term right ventricular pacing has been associated with an increased risk of heart failure and cardiomyopathy. The pathophysiology of cardiomyopathy associated with right ventricular pacing remains uncl... Objective: Long-term right ventricular pacing has been associated with an increased risk of heart failure and cardiomyopathy. The pathophysiology of cardiomyopathy associated with right ventricular pacing remains unclear. We aim to evaluate the burden and short-term outcomes of ventricular dyssynchrony after immediate permanent pacemaker implantation. Materials and Methods: This prospective cohort study examined consecutive patients who had permanent pacemaker implantation at Vajira Hospital in 2019. Left ventricular systolic function, specifically left ventricular ejection fraction (LVEF) and echocardiographic ventricular dyssynchrony parameters were assessed. The endpoints included the prevalence of ventricular dyssynchrony, new-onset cardiomyopathy, heart failure, and death. The correlation between QRS complex duration, the burden of ventricular pacing, and echocardiographic ventricular dyssynchrony was measured. Results: Thirty-six consecutive patients underwent pacemaker implantation. The prevalence of mechanical ventricular dyssynchrony was 22.2% using the interventricular conduction delay method, 41.7% using LV pre-ejection period method, and 11.1% using the septal posterior wall motion abnormality method. Electrical ventricular dyssynchrony was 86.1% and new-onset cardiomyopathy was 17.1% after 3 months of permanent pacemaker implantation. The right ventricular pacing of more than 20% was significantly associated with cardiomyopathy (p < 0.022) and heart failure (log-rank, p = 0.049) within 3 months. But heart failure was not associated with mechanical ventricular dyssynchrony parameters (log-rank, p = 0.610;hazard ratio [HR], 1.53;95% confidence interval [CI], 0.29 - 7.96;p = 0.613 for IVMD and log-rank, p = 0.398;HR, 0.04;95% CI, 0.01 - 3316.7 for SPWMD). Conclusion: Mechanical and electrical ventricular dyssynchrony are common findings in right ventricular pacing. High-burden right ventricular pacing after 3 months of permanent pacemaker implantation is often associated with cardiomyopathy and heart failure, but mechanical and electrical ventricular dyssynchrony does not predict a short-term decline in left ventricular systolic function and heart failure. 展开更多
关键词 Right ventricular Pacing ventricular Dyssynchrony PREDICTOR CORRELATION heart failure CARDIOMYOPATHY left ventricular ejection fraction Decline
下载PDF
A Brief Review of a Common Clinical Question: Intravenous Diltiazem or Metoprolol for Atrial Fibrillation with Rapid Ventricular Response?
15
作者 Zachary Visinoni Neeladri Misra Daniel Jurewitz 《World Journal of Cardiovascular Diseases》 2023年第9期550-555,共6页
Two classes of rate controlling medications—beta blockers (BBs) and non- dihydropyridine calcium channel blockers (CCBs)—are given to patients who present with atrial fibrillation (AF) with rapid ventricular respons... Two classes of rate controlling medications—beta blockers (BBs) and non- dihydropyridine calcium channel blockers (CCBs)—are given to patients who present with atrial fibrillation (AF) with rapid ventricular response (RVR). Both are Class I recommendations from the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Rhythm Society (HRS) for the management of AF with RVR. Multiple studies support the view that diltiazem is more effective than metoprolol, even though data from the AFFIRM trial suggests BBs are more frequently used. CCBs are generally avoided in AF with RVR patients who have concomitant heart failure with reduced ejection fraction (HFrEF) for concern of triggering decompensation. However, some recent studies indicate this idea may be unfounded. The aim of this article is to compare the efficacy of diltiazem and metoprolol for rate control in AF with RVR and examine the use of diltiazem in patients with both AF with RVR and HFrEF. 展开更多
关键词 Atrial Fibrillation Rapid ventricular Response DILTIAZEM METOPROLOL heart failure with reduced ejection fraction
下载PDF
冻干重组人脑利钠肽治疗年龄大于60岁HFrEF患者的临床研究
16
作者 王新亮 《淮海医药》 CAS 2022年第2期141-144,共4页
目的:探究冻干重组人脑利钠肽(rhBNP)对年龄大于60岁、左室射血分数降低型心衰(HFrEF)患者心功能及血清N端前体脑钠肽(NT-proBNP)水平的影响。方法:选取某院114例年龄大于60岁HFrEF患者为研究对象,根据患者就诊序号采用随机数字表法分... 目的:探究冻干重组人脑利钠肽(rhBNP)对年龄大于60岁、左室射血分数降低型心衰(HFrEF)患者心功能及血清N端前体脑钠肽(NT-proBNP)水平的影响。方法:选取某院114例年龄大于60岁HFrEF患者为研究对象,根据患者就诊序号采用随机数字表法分成对照组和研究组,每组57例。对照组接受琥珀酸美托洛尔缓释片(MSSRT)治疗,研究组接受rhBNP联合MSSRT治疗。比较2组患者总有效率、治疗前、治疗7 d后左室收缩期最大心肌弹性劲度(max EAV)、左室射血分数(LVEF)、血清NT-proBNP、心肌肌钙蛋白I2(cTnI I2)水平、心型脂肪酸结合蛋白(H-FABP)、肾素-血管紧张素-醛固酮(RAAS)系统指标[醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)、肾素(PRA)]及不良反应发生率。结果:研究组总有效率(94.74%)高于对照组(77.19%),差异有统计学意义(P<0.05);治疗7 d后,研究组LVEF、max EAV分别为(54.49±5.37)%、(9.54±1.69)N/cm2,均高于对照组的(47.51±4.72)%、(8.01±1.41)N/cm2,血清NT-proBNP、CTnII2、H-FABP、AngⅡ、ALD、PRA水平分别为(552.38±38.84)pmol/L、(0.13±0.03)ng/mL、(22.08±9.74)ng/mL、(98.75±7.48)pg/mL、(227.76±16.26)pg/mL、(1.25±0.13)ng/mL,均低于对照组的(612.39±43.57)pmol/L、(0.20±0.05)ng/mL、(37.59±11.64)ng/mL、(113.18±7.52)pg/mL、(253.46±18.41)pg/mL、(1.59±0.26)ng/mL(P<0.05);研究组治疗期间不良反应发生率(10.53%)与对照组(5.26%)比较,差异无统计学意义(P>0.05)。结论:在MSSRT治疗HFrEF患者基础上,加用rhBNP可进一步提高疗效,改善心功能,调节患者血清NT-proBNP、cTnI I2水平,抑制RAAS系统活性,且无明显其他不良反应,值得临床推广应用。 展开更多
关键词 心力衰竭 左室射血分数 冻干重组人脑利钠肽 心功能
下载PDF
β受体阻滞剂应用于小儿充血性心力衰竭的系统评价与Meta分析
17
作者 王亚丹 李辉 +2 位作者 刘金平 张坤贤 赵国艳 《中国药师》 CAS 2024年第2期345-356,共12页
目的 系统评价β受体阻滞剂对小儿充血性心力衰竭患者的疗效,为临床用药提供证据。方法 从PubMed、Embase、the Cochrane Library及CNKI、万方、维普数据库中检索相关前后对照试验与随机对照试验,检索时限自建库起至2023年10月31日。结... 目的 系统评价β受体阻滞剂对小儿充血性心力衰竭患者的疗效,为临床用药提供证据。方法 从PubMed、Embase、the Cochrane Library及CNKI、万方、维普数据库中检索相关前后对照试验与随机对照试验,检索时限自建库起至2023年10月31日。结局指标有左心室射血分数(LVEF)、左心室短轴缩短率(LVFS)、左心室舒张末期内径(LVDD)、左心室收缩末期内径(LVSD)、N端B型脑钠肽(NT-proBNP)、心率、血压及心功能改善情况。结果 共纳入20项符合标准的研究,包含1 068例患儿,包括扩张型心肌病、心内膜弹力纤维增生。Meta分析显示,在常规心力衰竭药物治疗的基础上,使用β受体阻滞剂(琥珀酸美托洛尔、比索洛尔及卡维地洛),对改善患儿LVEF[MD=13.06,95%CI(11.67,14.45),P <0.001]、LVFS [MD=6.96,95%CI(6.54,7.37),P <0.001]、LVDD [MD=-6.43,95%CI(-7.58,-5.28),P <0.001]和LVSD [MD=-8.30,95%CI(-8.83,-7.76),P <0.001]效果显著;也可改善患儿血压、心率、NT-proBNP和心功能。结论 在常规心力衰竭药物治疗的基础上使用β受体阻滞剂的联合方案可提高小儿充血性心力衰竭患者的心功能及改善心力衰竭症状,推荐将β受体阻滞剂积极应用于该类患儿的常规治疗方案中。 展开更多
关键词 充血性心力衰竭 儿童 Β受体阻滞剂 左心室射血分数 META分析
下载PDF
二参真武汤联合美托洛尔治疗左心室射血分数保留型心力衰竭患者的疗效及对其心功能和神经内分泌因子的影响
18
作者 盛晟 程晓昱 程丹 《世界中西医结合杂志》 2024年第7期1452-1457,共6页
目的探究二参真武汤联合美托洛尔治疗左心室射血分数保留型心力衰竭(Heart failure with preserved ejection fraction,HFpEF)患者的疗效及对其心功能和神经内分泌因子的影响。方法选取2021年6月-2023年6月期间就诊于安徽省中西医结合... 目的探究二参真武汤联合美托洛尔治疗左心室射血分数保留型心力衰竭(Heart failure with preserved ejection fraction,HFpEF)患者的疗效及对其心功能和神经内分泌因子的影响。方法选取2021年6月-2023年6月期间就诊于安徽省中西医结合医院心血管内科的HFpEF患者92例,依据简单随机数字表法分为对照组和研究组,每组各46例。两组患者均给予常规治疗,对照组在常规干预基础上口服美托洛尔,研究组在对照组基础上联合二参真武汤,两组患者均治疗4周。观察比较两组患者临床疗效、不良反应发生情况,治疗前后中医证候积分、心功能[左心室射血分数(Left ventricular ejection fractions,LVEF)、左心室收缩末内径(Left ventricular end systolic diameter,LVESD)、左心室舒张末内径(Left ventricular end diastolic diameter,LVEDD)、左心室等容舒张时间(Isovolumic relaxation time,IVRT)]、神经内分泌因子指标[醛固酮(Aldosterone,ALD)、血管紧张素Ⅱ(AngiotensinⅡ,AngⅡ)、去甲肾上腺素(Noradrenaline,NE)]水平、中性粒细胞明胶酶相关脂质运载蛋白(Neutrophil gelatinase-associated lipocalin,NGAL)、生长分化因子-15(Growth differentiation factor-15,GDF-15)水平。结果治疗后研究组治疗总有效率93.48%(43/46)明显高于对照组78.26%(36/46),差异有统计学意义(P<0.05)。治疗后两组患者胸胁作痛、心悸、气短喘息、浮肿与唇甲青紫、面色晦暗、畏寒肢冷分值均较治疗前降低,差异有统计学意义(P<0.05);且研究组中医证候积分明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者LVEF水平均较治疗前升高,LVESD、LVEDD、IVRT水平均较治疗前降低,差异有统计学意义(P<0.05);且研究组LVEF水平明显高于对照组,LVESD、LVEDD、IVRT水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清ALD、AngⅡ、NE水平均较治疗前降低,差异有统计学意义(P<0.05);且研究组神经内分泌因子水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者血清NGAL、GDF-15水平均较治疗前降低,差异有统计学意义(P<0.05);且研究组血清NGAL、GDF-15水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,研究组不良反应发生率4.35%(2/46)与对照组8.70%(4/46)比较,差异无统计学意义(P>0.05)。结论联合二参真武汤及美托洛尔治疗HFpEF,可缓解患者临床症状,调节ALD、AngⅡ、NE及NGAL、GDF-15水平,改善心功能,提升整体治疗效果,且具有安全性。 展开更多
关键词 二参真武汤 美托洛尔 左心室射血分数保留型心力衰竭 心功能 神经内分泌因子
下载PDF
沙库巴曲缬沙坦对射血分数保留的心力衰竭患者右心结构及功能的影响分析
19
作者 周伟 陈东 高玉 《中国循证心血管医学杂志》 2024年第7期830-833,845,共5页
目的探讨沙库巴曲缬沙坦对射血分数保留的心力衰竭(HFpEF)患者右心结构及功能的影响。方法选取2020年8月至2022年6月于安徽医科大学附属合肥医院心内科门诊收治的120例HFpEF患者,根据随机数字表法分为观察组和对照组各60例,观察组应用... 目的探讨沙库巴曲缬沙坦对射血分数保留的心力衰竭(HFpEF)患者右心结构及功能的影响。方法选取2020年8月至2022年6月于安徽医科大学附属合肥医院心内科门诊收治的120例HFpEF患者,根据随机数字表法分为观察组和对照组各60例,观察组应用沙库巴曲缬沙坦(50 mg,bid)治疗,对照组应用缬沙坦(50 mg,bid)治疗,比较观察组和对照组患者治疗后右心收缩功能、舒张功能指标的变化。结果治疗后,两组心肌做功指数(Tei index,Tei指数)较治疗前下降(P<0.05),右室面积变化分数(RVFAC)、三尖瓣环平面收缩期位移(TAPSE)、三尖瓣环侧壁收缩期峰流速(TAPSV)均较治疗前升高,其中观察组Tei指数较对照组下降,而RVFAC、TAPSE、TAPSV均较对照组升高(P<0.05)。同时肺动脉平均压(mPAP)、右心房容积指数(RAVI)、舒张期室间隔厚度(IVST)在缬沙坦或沙库巴曲缬沙坦治疗后均下降(P<0.05),右侧房室瓣环处心肌舒张早期峰值流速(Ve)/舒张晚期峰值流速(Va)较治疗前升高,其中观察组mPAP、RAVI、IVST均较对照组下降,Ve/Va较对照组升高(P<0.05)。结论沙库巴曲缬沙坦能有效改善HFpEF患者右心收缩及舒张功能,可通过降低炎症因子以及纤维化相关因子水平改善心室重构。 展开更多
关键词 沙库巴曲缬沙坦 左心室射血分数保留 心力衰竭
下载PDF
射血分数保留型心力衰竭患者心率变异性与左心室僵硬度的相关性
20
作者 梁仪 徐良洁 王春靓 《实用心电学杂志》 2024年第5期433-437,共5页
目的筛选反映射血分数保留型心力衰竭(heart failure with preserved ejection fraction,HFpEF)患者左心室僵硬度的敏感心率变异性(heart rate variability,HRV)指标,并评价其对HFpEF患者的预后评估价值。方法选取150例左心室射血分数(L... 目的筛选反映射血分数保留型心力衰竭(heart failure with preserved ejection fraction,HFpEF)患者左心室僵硬度的敏感心率变异性(heart rate variability,HRV)指标,并评价其对HFpEF患者的预后评估价值。方法选取150例左心室射血分数(LVEF)正常的患者,行24 h动态心电图及常规超声心动图检查。将入选患者分成正常对照组(68例)和HFpEF组(82例)。采用受试者工作特征曲线分析,筛选HRV指标中能反映HFpEF患者左心室僵硬度的敏感指标,并对主要终点事件进行随访。结果在HRV指标中,SDANN预测HFpEF的曲线下面积最大,达0.68(P<0.01),cut-off值90 ms。SDANN与左心室舒张期室壁应变呈负相关;SDANN越高,左心室僵硬度就越高。根据SDANN的cut-off值,HFpEF患者被分为高SDANN组(cut-off值≥90 ms,44例)和低SDANN组(cut-off值<90 ms,38例)。低SDANN组左心室僵硬度较低。生存曲线分析显示,高SDANN组的主要不良心脏事件发生率和全因死亡率较低SDANN组显著升高(P<0.05)。结论SDANN可作为HFpEF患者临床诊断及预后评估的敏感指标。 展开更多
关键词 心率变异性 左心室僵硬度 射血分数保留型心力衰竭 动态心电图
下载PDF
上一页 1 2 41 下一页 到第
使用帮助 返回顶部